glp 1 receptor agonists in idiopathic intracranial hypertension Treatment with GLP-1 is associated with significant weight loss and favorable headache outcomes | The Journal of Headache and Pain GLP-1 medications and pseudotumor cerebri

Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases

Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: A systematic review and meta-analysis

Any score greater than 8 kPA on VCTE should be referred to Hepatology for further assessment

Blood Pressure-Lowering Effects of GLP-1 Receptor Agonists Exenatide and Liraglutide: A Meta-Analysis of Clinical Trials

We vet everything on PubMed so you dont have to

Introduction The glucagon-like peptide-1 (GLP-1) is a 3031 amino acid incretin secreted by enteroendocrine L cells in the ileum and colon in response to nutritional stimuli such as glucose, fatty acids, and amino acids in the intestinal lumen